Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATRX NYSE:BON OTCMKTS:GLGLF NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRXAdhera Therapeutics$0.01$0.00$0.00▼$0.01$120K10.3560 shs1 shsBONBon Natural Life$1.52$1.39$1.14▼$73.75$254K-0.461.69 million shs90,797 shsGLGLFGLG Life Tech$0.00$0.01▼$1.12$430K1.84N/AN/AWINTWindtree Therapeutics$0.07-8.8%$0.57$0.06▼$195.00$2.14M0.575.65 million shs501,599 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRXAdhera Therapeutics0.00%0.00%+9,900.00%+9,900.00%+316.67%BONBon Natural Life0.00%+7.80%+18.75%-7.88%-96.62%GLGLFGLG Life Tech0.00%0.00%0.00%0.00%0.00%WINTWindtree Therapeutics0.00%-23.24%-87.56%-87.15%-99.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRXAdhera Therapeutics$0.01$0.00$0.00▼$0.01$120K10.3560 shs1 shsBONBon Natural Life$1.52$1.39$1.14▼$73.75$254K-0.461.69 million shs90,797 shsGLGLFGLG Life Tech$0.00$0.01▼$1.12$430K1.84N/AN/AWINTWindtree Therapeutics$0.07-8.8%$0.57$0.06▼$195.00$2.14M0.575.65 million shs501,599 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRXAdhera Therapeutics0.00%0.00%+9,900.00%+9,900.00%+316.67%BONBon Natural Life0.00%+7.80%+18.75%-7.88%-96.62%GLGLFGLG Life Tech0.00%0.00%0.00%0.00%0.00%WINTWindtree Therapeutics0.00%-23.24%-87.56%-87.15%-99.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRXAdhera Therapeutics 0.00N/AN/AN/ABONBon Natural Life 0.00N/AN/AN/AGLGLFGLG Life Tech 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.00479,352.05% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/ABONBon Natural Life$23.84M0.01$1.95 per share0.78$37.78 per share0.04GLGLFGLG Life Tech$10.62M0.00N/AN/A($2.00) per share0.00WINTWindtree TherapeuticsN/AN/AN/AN/A$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRXAdhera Therapeutics-$2.11MN/A0.00∞N/AN/AN/AN/AN/ABONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/AGLGLFGLG Life Tech$48.29M$1.970.00N/AN/A788.59%N/A-57.10%N/AWINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-207.34%-50.19%11/25/2025 (Estimated)Latest ATRX, GLGLF, WINT, and BON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q2 2025GLGLFGLG Life TechN/A-$0.03N/A-$0.59N/A$2.07 million8/19/2025Q2 2025WINTWindtree Therapeutics-$99.00-$3.06+$95.94-$3.06$3.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRXAdhera TherapeuticsN/AN/AN/AN/AN/ABONBon Natural LifeN/AN/AN/AN/AN/AGLGLFGLG Life TechN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRXAdhera TherapeuticsN/AN/AN/ABONBon Natural Life0.022.422.32GLGLFGLG Life TechN/A0.210.19WINTWindtree TherapeuticsN/A0.430.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRXAdhera TherapeuticsN/ABONBon Natural Life0.57%GLGLFGLG Life TechN/AWINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipATRXAdhera Therapeutics28.20%BONBon Natural Life26.48%GLGLFGLG Life TechN/AWINTWindtree Therapeutics0.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRXAdhera Therapeutics211.63 million8.35 millionNot OptionableBONBon Natural Life100167,000863,000Not OptionableGLGLFGLG Life Tech1238.39 millionN/ANot OptionableWINTWindtree Therapeutics3029.33 million3.66 millionNot OptionableATRX, GLGLF, WINT, and BON HeadlinesRecent News About These CompaniesShort Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 36.9%1 hour ago | americanbankingnews.comWindtree Therapeutics Approves Key Financial Structure ChangesSeptember 3, 2025 | msn.comWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingSeptember 2, 2025 | markets.businessinsider.comWindtree Therapeutics, Inc. Stockholders Approve Strategic Shift Toward Environmental Services and Biotech PartnershipsSeptember 2, 2025 | quiverquant.comQWarrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27, 2025 | msn.comBNB Treasury Firm Windtree Therapeutics Plunges 77% After Nasdaq Delisting NoticeAugust 22, 2025 | thecurrencyanalytics.comTBNB treasury company plunges 77% after Nasdaq delisting noticeAugust 22, 2025 | cointelegraph.comBNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delistingAugust 20, 2025 | fxstreet.comNasdaq to Delist BNB Treasury Firm Windtree Therapeutics, Stock Crashes 76%August 20, 2025 | coingape.comCWindtree Therapeutics Faces Nasdaq Delisting NoticeAugust 20, 2025 | msn.comWindtree Therapeutics Delays Q2 2025 Report FilingAugust 14, 2025 | tipranks.comWindtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025August 11, 2025 | globenewswire.comWindtree Therapeutics Terminates SEISMiC-C Clinical StudyAugust 11, 2025 | theglobeandmail.comWindtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study ResultsAugust 7, 2025 | msn.comWindtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock PatientsAugust 5, 2025 | taiwannews.com.twTWindtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy RolloutJuly 30, 2025 | msn.comWindtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and RedemptionJuly 29, 2025 | globenewswire.comWindtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto PivotJuly 26, 2025 | thecurrencyanalytics.comTWindtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time HighJuly 26, 2025 | techstory.inTWindtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency HoldingsJuly 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRX, GLGLF, WINT, and BON Company DescriptionsAdhera Therapeutics OTCMKTS:ATRX$0.01 0.00 (0.00%) As of 09/5/2025Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Bon Natural Life NYSE:BON$1.52 0.00 (0.00%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.50 -0.02 (-1.64%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.GLG Life Tech OTCMKTS:GLGLFGLG Life Tech Corporation researches for, develops, grows, refines, and produces natural sweeteners extracted from the stevia plant and monk fruit in Canada and internationally. It also offers P-Pro Plus, a pea protein product; REB M GOLD, a bioconverted Rebaudioside M and Rebaudioside D. sweetener; and natural ingredients. It serves in the food and beverage industry. The company was formerly known as GLG Life Tech Limited and changed its name to GLG Life Tech Corporation in March 2007. GLG Life Tech Corporation was incorporated in 1998 and is headquartered in Richmond, Canada.Windtree Therapeutics NASDAQ:WINT$0.07 -0.01 (-8.75%) As of 09/5/2025 03:43 PM EasternWindtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
